LeMaitre Vascular Inc (NASDAQ:LMAT) has been given an average recommendation of “Hold” by the nine brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $34.80.
Several research firms have issued reports on LMAT. Roth Capital raised LeMaitre Vascular from a “neutral” rating to a “buy” rating and dropped their price target for the company from $39.00 to $34.00 in a report on Monday, October 8th. Zacks Investment Research cut LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Wednesday, September 26th. BidaskClub cut LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Tuesday, October 9th. ValuEngine cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Monday, July 30th. Finally, Canaccord Genuity upped their price target on LeMaitre Vascular from $31.00 to $35.00 and gave the company a “hold” rating in a report on Monday, July 9th.
In other LeMaitre Vascular news, Director Michael H. Thomas sold 20,000 shares of LeMaitre Vascular stock in a transaction that occurred on Tuesday, October 30th. The shares were sold at an average price of $27.93, for a total transaction of $558,600.00. Following the transaction, the director now directly owns 20,000 shares in the company, valued at approximately $558,600. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman George W. Lemaitre sold 14,180 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, August 22nd. The stock was sold at an average price of $37.61, for a total transaction of $533,309.80. Following the transaction, the chairman now owns 3,118,266 shares in the company, valued at $117,277,984.26. The disclosure for this sale can be found here. Insiders sold 34,681 shares of company stock worth $1,110,462 in the last ninety days. 20.30% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. WINTON GROUP Ltd grew its position in LeMaitre Vascular by 125.0% during the 3rd quarter. WINTON GROUP Ltd now owns 20,521 shares of the medical instruments supplier’s stock worth $795,000 after purchasing an additional 11,401 shares in the last quarter. Cadence Capital Management LLC grew its position in LeMaitre Vascular by 20.1% during the 3rd quarter. Cadence Capital Management LLC now owns 83,497 shares of the medical instruments supplier’s stock worth $3,235,000 after purchasing an additional 13,984 shares in the last quarter. Wells Fargo & Company MN grew its position in LeMaitre Vascular by 51.8% during the 3rd quarter. Wells Fargo & Company MN now owns 220,289 shares of the medical instruments supplier’s stock worth $8,533,000 after purchasing an additional 75,165 shares in the last quarter. Kaizen Advisory LLC purchased a new position in LeMaitre Vascular during the 3rd quarter worth approximately $1,070,000. Finally, Victory Capital Management Inc. grew its position in LeMaitre Vascular by 62.6% during the 3rd quarter. Victory Capital Management Inc. now owns 9,564 shares of the medical instruments supplier’s stock worth $371,000 after purchasing an additional 3,681 shares in the last quarter. Hedge funds and other institutional investors own 81.37% of the company’s stock.
NASDAQ LMAT opened at $27.74 on Tuesday. The firm has a market capitalization of $524.72 million, a price-to-earnings ratio of 32.26, a P/E/G ratio of 2.20 and a beta of 0.99. LeMaitre Vascular has a 1 year low of $26.39 and a 1 year high of $41.28.
LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Friday, October 5th. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.21. The company had revenue of $24.17 million for the quarter, compared to analysts’ expectations of $26.06 million. LeMaitre Vascular had a return on equity of 18.49% and a net margin of 20.52%. On average, equities research analysts forecast that LeMaitre Vascular will post 1.03 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 6th. Shareholders of record on Tuesday, November 20th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Monday, November 19th. This represents a $0.28 annualized dividend and a dividend yield of 1.01%. LeMaitre Vascular’s dividend payout ratio is currently 32.56%.
About LeMaitre Vascular
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Recommended Story: Dividend Aristocrat Index
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.